Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Updates in immunotherapy for multiple myeloma: BiTEs & novel targets

Adam Sperling • 13 Jun 2022
EHA 2022
Multiple Myeloma Antibodies CAR-T

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on the most exciting developments in the field of immunotherapy for multiple myeloma, including BCMA-targeting CAR-T therapies, bispecific T-cell engagers (BiTEs), and novel target antigens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Adam Sperling

The impact of clonal hematopoiesis on treatment strategies for Waldenström's macroglobulinemia
1:04
The impact of clonal hematopoiesis on treatment strategies for Waldenström's macroglobulinemia
Adam Sperling • 18 Oct 2024
Detecting clonal hematopoiesis in patients with Waldenström's macroglobulinemia
1:08
Detecting clonal hematopoiesis in patients with Waldenström's macroglobulinemia
Adam Sperling • 18 Oct 2024
Clonal hematopoiesis increases the risk of progression in patients with asymptomatic WM
1:28
Clonal hematopoiesis increases the risk of progression in patients with asymptomatic WM
Adam Sperling • 18 Oct 2024
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
1:48
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
Adam Sperling • 27 Sep 2023

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Adam Sperling • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Adam Sperling • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Adam Sperling • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Adam Sperling • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals